NGM Biopharmaceuticals and partner Merck have generated a lot of excitement over their early-stage treatment for nonalcoholic steatohepatitis (NASH) and Type 2 diabetes, MK-3655, even though they’re well behind several rivals who are working on similar drugs. Now, they have new data from a phase 1b trial to back up what they hope will be their major selling point: a more convenient dosing schedule.